Therapeutic/prophylactic agent for prostate cancer
AssigneeGenomldea Inc.
InventorsYasufumi Kaneda, Yoshifumi Kawaguchi, Toshimitsu Itai
Life of this patent
Estimating the term…
Abstract
Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.
Claims9
A method of treating prostatic cancer, comprising administering to an individual in need thereof an effective amount of a wild-type Sendai virus envelope to a prostatic cancer patient, wherein the patient has a history of receiving endocrine therapy and bears a prostatic cancer whose androgen susceptibility has been partially or completely reduced.
Dependencies are inferred from the claim text.